Table II.

Extent to which Navigenics ELTR estimates contribute to prediction of self-reported PH of disease independently of traditional risk factors, including FH, gender, age, and ethnicity

Condition (conditions >1%)	Nagelkerke R Square	Navigenics ELTR		Family Historyb		Genderc		Age		Ethnicityd
		OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
Graves’ Disease/Thyroid	.214	1.194 (1.068–1.335)	.002	5.286 (4.037–6.921)	<.001	2.686 (1.823–3.958)	<.001	1.052 (1.040–1.065)	<.001	.880 (.610–1.270)	.495
Type 2 Diabetes/Diabetes	.119	1.035 (1.016–1.054)	<.001	5.507 (3.265–9.289)	<.001	.598 (.394–.909)	.016	1.050 (1.031–1.069)	<.001	.608 (.369–.999)	.050
Restless Leg Syndrome	.110	1.022 (.957–1.090)	.519	6.749 (4.744–9.600)	<.001	1.329 (.956–1.848)	.091	1.016 (1.003–1.030)	.020	1.916 (1.099–3.342)	.022
Heart Attack (Males)	.171	1.031 (.966–1.100)	.364	1.953 (.678–5.628)	.215	NA	NA	1.123 (1.073–1.176)	<.001	.605 (.129–2.843)	.525
Prostate Cancer (Males)	.255	1.033 (.974–1.096)	.282	2.212 (.751–6.515)	.150	NA	NA	1.146 (1.096–1.199)	<.001	NA	NA
Breast Cancer (Females)	.115	1.043 (.962–1.130)	.306	1.363 (.753–2.465)	.306	NA	NA	1.089 (1.059–1.119)	<.001	1.118 (.454–2.754)	.808
Melanomaa	.121	.932 (.658–1.319)	.690	3.292 (1.380–7.848)	.007	.650 (.281–1.503)	.314	1.071 (1.034–1.110)	<.001	NA	NA

^a“Updated” condition; based on subset of sample (see Supplemental Methods)

^bFamily history coded as follows: 1=+FH, 0=−FH

^cGender coded as follows: 1=Female, 0=Male

^dEthnicity coded as follows: 1=self-reported Caucasian, 0=self-reported non-Caucasian (see Supplemental Methods